Merck & Co.

• 10-QQ2 FY2026RestructuringImpairment / charge

  Filed Aug 7

  Cidara and Terns acquired-research charges drove a GAAP loss despite growth from Winrevair and Animal Health.

  • Revenue$16.6BYoY +5.1%
  • Net income−$1.3Bvs $4.4B year ago

• 8-KEarningsGuidance loweredImpairment / charge

  Filed Aug 4

  Terns acquisition charge drove losses and a lower EPS outlook, while KEYTRUDA QLEX contributed to oncology growth.

• 8-KShareholder vote

  Filed May 28

  Shareholders rejected all three shareholder proposals and approved executive compensation.

• 8-KDebt financing

  Filed May 22

  Closed a public note offering spanning 2028–2056 maturities, adding fixed- and floating-rate debt.

• 10-QQ1 FY2026MixedRestructuringImpairment / charge

  Filed May 4

  Cidara’s influenza-pipeline acquisition drove a GAAP loss despite sales growth led by Keytruda and Winrevair.

  • Revenue$16.3BYoY +4.9%
  • Net income−$4.2Bvs $5.1B year ago

• 8-KPositiveEarningsGuidance raisedImpairment / charge

  Filed Apr 30

  Cidara acquisition charge drove quarterly losses; KEYTRUDA and WINREVAIR fueled sales growth.

• 10-KFY2025Restructuring

  Filed Feb 24

  China Gardasil inventory overhang blunted Keytruda and Winrevair growth; launches and acquisitions seek replacement revenue.

  • Revenue$65.0BYoY +1.3%
  • Net income$18.3BYoY +6.6%

• 8-KEarningsNew guidanceImpairment / charge

  Filed Feb 3

  Gardasil slump tempers KEYTRUDA and Animal Health gains; Cidara acquisition charge weighs on 2026 non-GAAP EPS outlook

Coverage: 10-K filings filed since Feb 24, 2026; 10-Q since May 4, 2026; 8-K since Feb 3, 2026.

Request longer coverage

Company data: Wikidata Q247489